Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Prostatic Neoplasms 9Leukemia, Myeloid, Acute 9Endometrial Neoplasms 8Breast Neoplasms 7Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lung Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Multiple Myeloma 4Melanoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Colorectal Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Neuroblastoma 3Mouth Neoplasms 3Lymphoma, Follicular 3Leukemia 3Esophageal Neoplasms 3Brain Neoplasms 3

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Docetaxel 70Carboplatin 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Observation × Clear all
NCT06933966 2025-04-18

ATTENUATION

Centre Leon Berard

Phase 2 Not yet recruiting
120 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT06272214 2024-07-16

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Zhejiang Cancer Hospital

Phase 2 Recruiting
146 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡